Enavogliflozin

Last updated
Enavogliflozin
Enavogliflozin.svg
Clinical data
Other namesDWP16001
ATC code
Identifiers
  • (2S,3R,4R,5S,6R)-2-{7-chloro-6-[(4-cyclopropylphenyl)methyl]-2,3-dihydro-1-benzofuran-4-yl}-6-(hydroxymethyl)oxane-3,4,5-triol
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C24H27ClO6
Molar mass 446.92 g·mol−1
3D model (JSmol)
  • OC[C@H]1O[C@@H](c2cc(Cc3ccc(C4CC4)cc3)c(Cl)c3c2CCO3)[C@H](O)[C@@H](O)[C@@H]1O
  • InChI=1S/C24H27ClO6/c25-19-15(9-12-1-3-13(4-2-12)14-5-6-14)10-17(16-7-8-30-23(16)19)24-22(29)21(28)20(27)18(11-26)31-24/h1-4,10,14,18,20-22,24,26-29H,5-9,11H2/t18-,20-,21+,22-,24+/m1/s1
  • Key:KORCWPOBTZTAFI-YVTYUBGGSA-N

Enavogliflozin (DWP16001/GCC5694A) is a selective SLC5A2 and SGLT2 inhibitor developed to treat diabetes and obesity. [1] [2] [3] [4] [5] It was developed by GC Pharma [6] [7] and Daewoong Pharmaceutical. [7]

Enavogliflozin has been approved for clinical use in South Korea, [7] and Ecuador, [8] and applied for approval in Brazil, Mexico, Peru, and Colombia. [8]

References

  1. ↑ Hwang, Jun Gi; Lee, SeungHwan; Huh, Wan; Han, Jumi; Oh, Jaeseong; Jang, In-Jin; Yu, Kyung-Sang (September 2022). "Dose-dependent glucosuria of DWP16001, a novel selective sodium–glucose cotransporter-2 inhibitor, in healthy subjects". British Journal of Clinical Pharmacology. 88 (9): 4100–4110. doi: 10.1111/bcp.15348 . PMID   35395697.
  2. ↑ Kim, Ju-Hyun; Kim, Dong Kyun; Choi, Won-Gu; Ji, Hye-Young; Choi, Ji-Soo; Song, Im-Sook; Lee, Sangkyu; Lee, Hye Suk (11 September 2020). "In Vitro Metabolism of DWP16001, a Novel Sodium-Glucose Cotransporter 2 Inhibitor, in Human and Animal Hepatocytes". Pharmaceutics. 12 (9): 865. doi: 10.3390/pharmaceutics12090865 . PMC   7558535 . PMID   32932946.
  3. ↑ Kim, Byungwook; Huh, Ki Young; Hwang, Jun Gi; Nah, JaeJin; Huh, Wan; Cho, Jae Min; Jang, In-Jin; Yu, Kyung-Sang; Kim, Yun; Lee, SeungHwan (April 2023). "Pharmacokinetic and pharmacodynamic interaction between DWP16001, an sodium–glucose cotransporter 2 inhibitor and metformin in healthy subjects". British Journal of Clinical Pharmacology. 89 (4): 1462–1470. doi:10.1111/bcp.15613. PMID   36422809. S2CID   253838705.
  4. ↑ Rhee, Beomseok; Mahbubur, Rahman Md; Jin, Changfan; Choi, Ji-Soo; Lim, Hyun-Woo; Huh, Wan; Park, Joon Seok; Han, Jumi; Kim, Sokho; Lee, Youngwon; Park, Jinho (December 2022). "Evaluation of safety and anti-obesity effects of DWP16001 in naturally obese dogs". BMC Veterinary Research. 18 (1): 237. doi: 10.1186/s12917-022-03324-2 . PMC   9214997 . PMID   35733159.
  5. ↑ Yoon, Sukyong; Park, Min Soo; Jin, Byung Hak; Shin, Hyobin; Na, Jaejin; Huh, Wan; Kim, Choon Ok (3 July 2023). "Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter-2 inhibitor, with phentermine in healthy subjects". Expert Opinion on Drug Metabolism & Toxicology. 19 (7): 479–485. doi:10.1080/17425255.2023.2249397. PMID   37593838. S2CID   265846294.
  6. ↑ Kong, Young Kyu; Song, Kwang-Seop; Jung, Myung Eun; Kang, Misuk; Kim, Hyeon Jung; Kim, Min Ju (2022-01-15). "Discovery of GCC5694A: A potent and selective sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes". Bioorganic & Medicinal Chemistry Letters. 56 128466. doi: 10.1016/j.bmcl.2021.128466 . ISSN   0960-894X.
  7. 1 2 3 Kim, Min-Soo; Song, Yoo-Kyung; Choi, Ji-Soo; Ji, Hye Young; Yang, Eunsuk; Park, Joon Seok; Kim, Hyung Sik; Kim, Min-Joo; Cho, In-Kyung; Chung, Suk-Jae; Chae, Yoon-Jee; Lee, Kyeong-Ryoon (2023-03-14). "Physiologically Based Pharmacokinetic Modelling to Predict Pharmacokinetics of Enavogliflozin, a Sodium-Dependent Glucose Transporter 2 Inhibitor, in Humans". Pharmaceutics. 15 (3): 942. doi: 10.3390/pharmaceutics15030942 . ISSN   1999-4923. PMC   10058973 . PMID   36986803.
  8. 1 2 "Daewoong Pharmaceutical's diabetes drug wins approval in Ecuador - 매일경제 영문뉴스 펄스(Pulse)". Pulse (in Korean). 2024. Retrieved 2025-04-04.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.